Innovax-ND-IBD-ILT (--) - Concentrate and solvent for suspension for injection

Authorised

- Turkey herpesvirus, strain HVT/ND/IBD/ILT (cell-associated), expressing fusion protein gene of Newcastle disease virus and VP2 protein gene of Infectious bursal disease virus and gD and gI glycoproteins genes of Infectious laryngotracheitis virus, Live

Product identification

Medicine name:
Innovax-ND-IBD-ILT (--) - Concentrate and solvent for suspension for injection

Active substance:
Turkey herpesvirus, strain HVT/ND/IBD/ILT (cell-associated), expressing fusion protein gene of Newcastle disease virus and VP2 protein gene of Infectious bursal disease virus and gD and gI glycoproteins genes of Infectious laryngotracheitis virus, Live

Target species:
Chicken
Chicken (embryonated eggs)

Route of administration:
In ovo
Subcutaneous use

Product details

Active substance and strength:
Turkey herpesvirus, strain HVT/ND/IBD/ILT (cell-associated), expressing fusion protein gene of Newcastle disease virus and VP2 protein gene of Infectious bursal disease virus and gD and gI glycoproteins genes of Infectious laryngotracheitis virus, Live
Presentation_strength:10^3.2 – 10^4.6 PFU Reference:In House Index:0

Pharmaceutical form:
Concentrate and solvent for suspension for injection

Withdrawal period by route of administration:
In ovo:

- **Chicken**
  - Not applicable. 0 day Zero days
- **Chicken (embryonated eggs)**
  - Not applicable. 0 day Zero days

Subcutaneous use:

- **Chicken**
  - Not applicable. 0 day Zero days
- **Chicken (embryonated eggs)**
  - Not applicable. 0 day Zero days

Anatomical therapeutic chemical veterinary (ATCvet) codes:
QI01AD20

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:
Valid

Authorised in:
Austria , Belgium , Bulgaria , Croatia , Cyprus , Czechia , Denmark , Estonia , Finland , France , Germany , Greece , Hungary , Iceland , Ireland , Italy , Latvia , Liechtenstein , Lithuania , Luxembourg , Malta , Netherlands , Norway , Poland , Portugal , Romania , Slovakia , Slovenia , Spain , Sweden , United Kingdom (Northern Ireland)

Package description:
Packaging:Concentrate: ampoule (Type I glass), Package_size:Concentrate: 1 ampoule, Content:Concentrate: 2000 doses
Packaging:Concentrate: ampoule (Type I glass), Package_size:Concentrate: 1 ampoule, Content:Concentrate: 4000 doses

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Full application - new active substance (Article 8 of Regulation (EU) 2019/6)

Marketing authorisation holder:
INTERVET INTERNATIONAL B.V.

Marketing authorisation date:
4/07/2025

Manufacturing sites for batch release:
Intervet International B.V.

Responsible authority:
European Commission

Authorisation number:
This information is not available for this product.

Date of authorisation status change:
4/07/2025

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Combined File of all Documents

English (PDF)
Published on: 18/07/2025
Download

ema-puar-v6442-innovaxndibdilt-initial-en.pdf